Pirtobrutinib Combined with Venetoclax and Rituximab Improves Progression Free Survival
Trial shows pirtobrutinib improves survival for chronic lymphocytic leukemia
Adding pirtobrutinib to a venetoclax-rituximab regimen significantly extends progression-free survival in patients with chronic lymphocytic …
A new combination treatment involving pirtobrutinib may help patients with chronic lymphocytic leukemia live longer without their cancer pro…
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age
Ten Years on One Pill: What Long-Term Ibrutinib Revealed
This investigator-sponsored phase 2 study evaluated single-agent ibrutinib in 84 patients with chronic lymphocytic leukemia (CLL) harboring …
A decade of follow-up shows a daily pill can give high-risk leukemia patients years of control, but staying on it is not easy.
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients
Two CLL patients saw kidney condition improve after targeted cancer treatment
A case report describes two patients with chronic lymphocytic leukemia (CLL) and concomitant nephrotic syndrome.
Two CLL patients saw kidney problems improve after targeted cancer treatment, resolving symptoms and reducing urine protein within weeks.
Research across Leukemia
Related studies from across the Leukemia family.
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Treosulfan-fludarabine improves 24-month event-free survival to 65% versus 53% in AML patients
Treosulfan Shows Better Outcomes for Patients with Acute Myeloid Leukemia
This Phase 3 randomized trial subgroup analysis of 352 patients with AML undergoing alloHCT found treosulfan-fludarabine superior to reduced…
A new analysis of a Phase 3 trial suggests treosulfan may offer better survival rates and fewer complications for patients with acute myeloi…
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML
Lower Dasatinib Dose May Improve Tolerability for Leukemia Patients
This meta-analysis of 7 nonoverlapping reports compared dasatinib 50 mg and 100 mg in adults with chronic-phase chronic myeloid leukemia. Th…
A lower daily dose of dasatinib may offer similar effectiveness with fewer side effects for adults with chronic-phase chronic myeloid leukem…
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients
Trial Shows Early Markers Predict Success in Chronic Myeloid Leukemia
This observational study of 431 patients with chronic myeloid leukemia (CML) on second-generation TKIs found that the 6-month IS value is a …
New data from a Phase 3 trial shows that early markers can help predict which patients with chronic myeloid leukemia may reach specific trea…
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
Leukapheresis not clearly linked to lower 30-day mortality in AML with hyperleukocytosis
Leukapheresis Shows No Clear Early Death Benefit in AML
This meta-analysis of 1406 adults with AML and hyperleukocytosis found that leukapheresis was not clearly associated with lower 30-day morta…
A review of 1406 AML patients found leukapheresis did not clearly lower 30-day death risk. Evidence is weak.
AML infiltration of bile duct identified as primary cause of acute pancreatitis in case report
Leukemia Cells Found as Cause of Severe Pancreatitis
This case report and literature review describes a 34-year-old man with acute pancreatitis and type 2 diabetes, where acute myeloid leukemia…
A rare case shows how a specific type of leukemia can infiltrate the pancreas and cause severe inflammation in patients with diabetes.
IV-PEG asparaginase compared to IM-EC in children with acute lymphoblastic leukemia
PEG-asparaginase shows lower toxicity in childhood leukemia trial
This Phase 3 randomized controlled trial evaluated intravenous PEG-asparaginase (IV-PEG) versus intramuscular native E. coli L-asparaginase …
A new trial finds that PEG-asparaginase may cause fewer side effects than standard treatment for children with leukemia.
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework
One patient's leukemia remission offers clues for rare diagnosis
This systematic review with a case report describes a patient with Philadelphia chromosome-positive leukemia who achieved complete remission…
A patient with a rare leukemia achieved deep remission for 35 months. The case highlights how to tell apart two similar-looking blood cancer…
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia
Imatinib works for CML in child with high platelets
This case report describes a pediatric patient with isolated thrombocytosis who achieved a complete cytogenetic response to imatinib after f…
A child with high platelets and no response to standard therapy was found to have CML and responded to imatinib.
Venetoclax plus intensive chemo yields 63.79% ORR in relapsed/refractory AML meta-analysis
Venetoclax combo shows promise for hard-to-treat leukemia
A meta-analysis of 235 patients with relapsed/refractory AML found that venetoclax combined with intensive chemotherapy achieved a pooled ov…
For patients with relapsed AML, venetoclax plus intensive chemo led to a 64% response rate in a new analysis.